Ongoing and future directions in percutaneous treatment of mitral regurgitation

ABSTRACT

Introduction: Mitral regurgitation (MR) is one of the major valvular disease. Although surgical mitral valve (MV) repair is the standard of care for patients with severe MR, an unmet need exists in the management of patients with severe symptomatic MR and high surgical risk. Transcatheter MV therapies are alternative treatment option in such patients with moderate to severe and symptomatic MR.

Areas covered: Literatures to direct the reader to important further reading were searched with relevant websites; www.ncbi.nlm.nih.gov/pubmed using search word ‘transcatheter mitral intervention’.

Expert commentary: A variety of transcatheter techniques have emerged for the percutaneous treatment of MR. We should carefully select one or combination procedure for each patient as an ideal tailor-made transcatheter MV therapy in order to improve the outcomes.

KEYWORDS:

• Mitral regurgitation
• mitral valve
• transcatheter mitral intervention
• transcatheter mitral valve repair
• transcatheter mitral valve replacement

Declaration of interest

F. Maisano is a consultant for St Jude Medical, Edwards Lifesciences, Abbott Vascular, Medtronic and Valtech and the cofounder of and shareholder of 4Tech Cardio and receives royalties from Edwards Lifesciences. M. Taramasso is consultant for St Jude Medical. A. Guidotti is a consultant for Valtech. F. Nietlispach is consultant for St Jude Medical, Medtronic and Edwards Lifesciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.